What's new

Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion

Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion

Mar 28, 2025 - 11:52
 0
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Osvyrti, denosumab, Status: Opinion
Read More

Tags:

Previous Article

Human medicines European public assessment report (EPAR): Cinainu, dry aqueous e...

Next Article

Human medicines European public assessment report (EPAR): Xoanacyl, ferric citra...

Related Posts

Product Management Service (PMS) webinar on Product User Interface (PUI) edit functionalities for industry users, Online, from 28 January 2025, 10:00 (CET) to 28 January 2025, 12:00 (CET)

Product Management Service (PMS) webinar on Product Use...

Feb 9, 2025  0

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 26, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, Mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0534/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 13, 2025  0